Abstract
Hepatitis E virus (HEV) is the most prevalent hepatitis virus worldwide. Genotypes 3 (HEV3) and 4 (HEV4) as well as rat HEV can lead to chronic hepatitis E and cirrhosis in immunosuppressed patients. Within the last decade, several options for treating chronic hepatitis have been developed and have achieved a sustained virological response. However, there are still unmet needs such as optimizing immunosuppression to allow HEV clearance with or without ribavirin, as well as alternative therapies to ribavirin that are discussed in this paper.
| Original language | English |
|---|---|
| Article number | 2116 |
| Journal | Viruses |
| Volume | 14 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 25 Sept 2022 |
Bibliographical note
Publisher Copyright: © 2022 by the authors.UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Unmet Needs for the Treatment of Chronic Hepatitis E Virus Infection in Immunocompromised Patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver